Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis

Mehdi Kardoust Parizi, Mohammad Abufaraj, Harun Fajkovic, Shoji Kimura, Takehiro Iwata, David D'Andrea, Pierre I. Karakiewicz, Shahrokh F. Shariat

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Aim: To evaluate the association between testosterone replacement therapy (TRT) in prostate cancer (CaP) patients who underwent definitive local therapy with curative intent with biochemical recurrence (BCR). Materials and methods: A literature search using PubMed, Scopus, Web of Science, and Cochrane Library was conducted on November 2018 to identify relevant studies according to the Preferred Reporting Items for Systematic Review and Meta Analysis guidelines. The pooled BCR rate in CaP men treated with TRT after definitive local therapy with curative intent was calculated using a random effects model. Results: Twenty-one studies were eligible. The overall pooled BCR rate was 0.01 (95%CI 0.00–0.02) suggesting a lack of association between TRT and BCR; there was no heterogeneity among included studies (I2 = 24.34%, P = 0.15). In subgroup analyses, pooled BCR rates were 0.00 (95%CI 0.00–0.02) in patients treated with radical prostatectomy and 0.02 (95%CI 0.00–0.04) in patients treated with external beam radiation therapy, brachytherapy, cryotherapy, or high intensity focused ultrasound; there was no heterogeneity in the subgroup analyses (I2 = 19.88%, P = 0.18). Conclusions: In this systematic review and meta-analysis, we did not observe higher rate of BCR after TRT for nonmetastatic CaP patients after definitive local therapy. Based on these data, others and we have outlined a phase I/II trial assessing the safety and benefits of TRT in select men with secondary symptomatic hypogonadism who have no active disease after definitive local CaP therapy with curative intent.

Original languageEnglish
Pages (from-to)637-646
Number of pages10
JournalUrologic Oncology: Seminars and Original Investigations
Volume37
Issue number10
DOIs
Publication statusPublished - Oct 2019

Fingerprint

Survivors
Testosterone
Meta-Analysis
Prostatic Neoplasms
Safety
Recurrence
Therapeutics
Library Science
Cryotherapy
Hypogonadism
Brachytherapy
Prostatectomy
PubMed
Radiotherapy
Guidelines

Keywords

  • Prostate cancer
  • Radiation therapy
  • Radical prostatectomy
  • Testosterone deficiency
  • Testosterone Replacement therapy

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy : A systematic literature review and meta-analysis. / Kardoust Parizi, Mehdi; Abufaraj, Mohammad; Fajkovic, Harun; Kimura, Shoji; Iwata, Takehiro; D'Andrea, David; Karakiewicz, Pierre I.; Shariat, Shahrokh F.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 37, No. 10, 10.2019, p. 637-646.

Research output: Contribution to journalReview article

Kardoust Parizi, Mehdi ; Abufaraj, Mohammad ; Fajkovic, Harun ; Kimura, Shoji ; Iwata, Takehiro ; D'Andrea, David ; Karakiewicz, Pierre I. ; Shariat, Shahrokh F. / Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy : A systematic literature review and meta-analysis. In: Urologic Oncology: Seminars and Original Investigations. 2019 ; Vol. 37, No. 10. pp. 637-646.
@article{28f80e04183547d1be8735e73e67b65c,
title = "Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis",
abstract = "Aim: To evaluate the association between testosterone replacement therapy (TRT) in prostate cancer (CaP) patients who underwent definitive local therapy with curative intent with biochemical recurrence (BCR). Materials and methods: A literature search using PubMed, Scopus, Web of Science, and Cochrane Library was conducted on November 2018 to identify relevant studies according to the Preferred Reporting Items for Systematic Review and Meta Analysis guidelines. The pooled BCR rate in CaP men treated with TRT after definitive local therapy with curative intent was calculated using a random effects model. Results: Twenty-one studies were eligible. The overall pooled BCR rate was 0.01 (95{\%}CI 0.00–0.02) suggesting a lack of association between TRT and BCR; there was no heterogeneity among included studies (I2 = 24.34{\%}, P = 0.15). In subgroup analyses, pooled BCR rates were 0.00 (95{\%}CI 0.00–0.02) in patients treated with radical prostatectomy and 0.02 (95{\%}CI 0.00–0.04) in patients treated with external beam radiation therapy, brachytherapy, cryotherapy, or high intensity focused ultrasound; there was no heterogeneity in the subgroup analyses (I2 = 19.88{\%}, P = 0.18). Conclusions: In this systematic review and meta-analysis, we did not observe higher rate of BCR after TRT for nonmetastatic CaP patients after definitive local therapy. Based on these data, others and we have outlined a phase I/II trial assessing the safety and benefits of TRT in select men with secondary symptomatic hypogonadism who have no active disease after definitive local CaP therapy with curative intent.",
keywords = "Prostate cancer, Radiation therapy, Radical prostatectomy, Testosterone deficiency, Testosterone Replacement therapy",
author = "{Kardoust Parizi}, Mehdi and Mohammad Abufaraj and Harun Fajkovic and Shoji Kimura and Takehiro Iwata and David D'Andrea and Karakiewicz, {Pierre I.} and Shariat, {Shahrokh F.}",
year = "2019",
month = "10",
doi = "10.1016/j.urolonc.2019.06.007",
language = "English",
volume = "37",
pages = "637--646",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy

T2 - A systematic literature review and meta-analysis

AU - Kardoust Parizi, Mehdi

AU - Abufaraj, Mohammad

AU - Fajkovic, Harun

AU - Kimura, Shoji

AU - Iwata, Takehiro

AU - D'Andrea, David

AU - Karakiewicz, Pierre I.

AU - Shariat, Shahrokh F.

PY - 2019/10

Y1 - 2019/10

N2 - Aim: To evaluate the association between testosterone replacement therapy (TRT) in prostate cancer (CaP) patients who underwent definitive local therapy with curative intent with biochemical recurrence (BCR). Materials and methods: A literature search using PubMed, Scopus, Web of Science, and Cochrane Library was conducted on November 2018 to identify relevant studies according to the Preferred Reporting Items for Systematic Review and Meta Analysis guidelines. The pooled BCR rate in CaP men treated with TRT after definitive local therapy with curative intent was calculated using a random effects model. Results: Twenty-one studies were eligible. The overall pooled BCR rate was 0.01 (95%CI 0.00–0.02) suggesting a lack of association between TRT and BCR; there was no heterogeneity among included studies (I2 = 24.34%, P = 0.15). In subgroup analyses, pooled BCR rates were 0.00 (95%CI 0.00–0.02) in patients treated with radical prostatectomy and 0.02 (95%CI 0.00–0.04) in patients treated with external beam radiation therapy, brachytherapy, cryotherapy, or high intensity focused ultrasound; there was no heterogeneity in the subgroup analyses (I2 = 19.88%, P = 0.18). Conclusions: In this systematic review and meta-analysis, we did not observe higher rate of BCR after TRT for nonmetastatic CaP patients after definitive local therapy. Based on these data, others and we have outlined a phase I/II trial assessing the safety and benefits of TRT in select men with secondary symptomatic hypogonadism who have no active disease after definitive local CaP therapy with curative intent.

AB - Aim: To evaluate the association between testosterone replacement therapy (TRT) in prostate cancer (CaP) patients who underwent definitive local therapy with curative intent with biochemical recurrence (BCR). Materials and methods: A literature search using PubMed, Scopus, Web of Science, and Cochrane Library was conducted on November 2018 to identify relevant studies according to the Preferred Reporting Items for Systematic Review and Meta Analysis guidelines. The pooled BCR rate in CaP men treated with TRT after definitive local therapy with curative intent was calculated using a random effects model. Results: Twenty-one studies were eligible. The overall pooled BCR rate was 0.01 (95%CI 0.00–0.02) suggesting a lack of association between TRT and BCR; there was no heterogeneity among included studies (I2 = 24.34%, P = 0.15). In subgroup analyses, pooled BCR rates were 0.00 (95%CI 0.00–0.02) in patients treated with radical prostatectomy and 0.02 (95%CI 0.00–0.04) in patients treated with external beam radiation therapy, brachytherapy, cryotherapy, or high intensity focused ultrasound; there was no heterogeneity in the subgroup analyses (I2 = 19.88%, P = 0.18). Conclusions: In this systematic review and meta-analysis, we did not observe higher rate of BCR after TRT for nonmetastatic CaP patients after definitive local therapy. Based on these data, others and we have outlined a phase I/II trial assessing the safety and benefits of TRT in select men with secondary symptomatic hypogonadism who have no active disease after definitive local CaP therapy with curative intent.

KW - Prostate cancer

KW - Radiation therapy

KW - Radical prostatectomy

KW - Testosterone deficiency

KW - Testosterone Replacement therapy

UR - http://www.scopus.com/inward/record.url?scp=85068460468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068460468&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2019.06.007

DO - 10.1016/j.urolonc.2019.06.007

M3 - Review article

C2 - 31296421

AN - SCOPUS:85068460468

VL - 37

SP - 637

EP - 646

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

IS - 10

ER -